RAS : Past, Present, and Future, Hardcover by O'bryan, John P. (EDT); Piazza,...
165,43 €
2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once “undruggable?.
Jetzt bei Ebay:
